{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:27:33Z","timestamp":1783348053148,"version":"3.54.6"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T00:00:00Z","timestamp":1778371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer Limited","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13396-2","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T16:35:37Z","timestamp":1778430937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Antimicrobial susceptibility study to compare the in vitro activity of antimicrobial agents in the Philippines against Enterobacterales and Pseudomonas aeruginosa from different infection sites: results from ATLAS surveillance program (2018\u20132021)"],"prefix":"10.1186","volume":"26","author":[{"given":"Myrna","family":"Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"Lagamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Yvette","family":"Barez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidehi","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Payawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,10]]},"reference":[{"key":"13396_CR1","unstructured":"Antimicrobial Resistance Factsheet. https:\/\/www.who.int\/docs\/default-source\/antimicrobial-resistance\/amr-factsheet.pdf. Accessed 18 Feb 2026."},{"key":"13396_CR2","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"10325","key":"13396_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(21)02724-0.","journal-title":"Lancet"},{"key":"13396_CR4","unstructured":"Antimicrobial. resistance.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance#:~:text=AMR%20affects%20countries%20in%20all,of%20modern%20medicine%20at%20risk. Accessed 18 Feb 2026."},{"issue":"4","key":"13396_CR5","doi-asserted-by":"publisher","first-page":"e246","DOI":"10.1016\/s2666-5247(22)00029-5","volume":"3","author":"JPG Robredo","year":"2022","unstructured":"Robredo JPG, Eala MAB, Paguio JA, Salamat MSS, Celi LAG. The challenges of combatting antimicrobial resistance in the Philippines. Lancet Microbe. 2022;3(4):e246. https:\/\/doi.org\/10.1016\/s2666-5247(22)00029-5.","journal-title":"Lancet Microbe"},{"key":"13396_CR6","unstructured":"Global Research on AntiMicrobial resistance (GRAM). The burden of antimicrobial resistance (AMR) in Philippines. https:\/\/www.healthdata.org\/sites\/default\/files\/2023-09\/Philippines.pdf. Accessed 18 Feb 2026."},{"key":"13396_CR7","unstructured":"Philippine National Action Plan on Antimicrobial. Resistance 2019\u20132023. https:\/\/cdn.who.int\/media\/docs\/default-source\/antimicrobial-resistance\/amr-spc-npm\/nap-library\/philippine-national-action-plan-on-amr-2019-2023-final.pdf?sfvrsn=8bbe1fdb_1. Accessed 18 Feb 2026."},{"key":"13396_CR8","unstructured":"DOH. RITM highlight importance of surveillance systems to understand the burden of antimicrobial resistance. https:\/\/ritm.gov.ph\/ritm-conducts-ndf-2023\/. Accessed 18 Feb 2026."},{"issue":"8","key":"13396_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/pathogens12081019","volume":"12","author":"AMS Abordo","year":"2023","unstructured":"Abordo AMS, Carascal MB, Remenyi R, Dalisay DS, Saludes JP. Clinically Isolated beta-Lactam-Resistant Gram-Negative Bacilli in a Philippine Tertiary Care Hospital Harbor Multi-Class beta-Lactamase Genes. Pathogens. 2023;12(8):1019. https:\/\/doi.org\/10.3390\/pathogens12081019.","journal-title":"Pathogens"},{"issue":"2","key":"13396_CR10","doi-asserted-by":"publisher","first-page":"e0065122","DOI":"10.1128\/msphere.00651-22","volume":"8","author":"MF Mojica","year":"2023","unstructured":"Mojica MF, De La Cadena E, Garcia-Betancur JC, Porras J, Novoa-Caicedo I, Paez-Zamora L, et al. Molecular Mechanisms of Resistance to Ceftazidime\/Avibactam in Clinical Isolates of Enterobacterales and Pseudomonas aeruginosa in Latin American Hospitals. mSphere. 2023;8(2):e0065122. https:\/\/doi.org\/10.1128\/msphere.00651-22.","journal-title":"mSphere"},{"key":"13396_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jgar.2021.11.011","volume":"29","author":"SH Lob","year":"2022","unstructured":"Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, et al. In vitro activity of ceftolozane\/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017\u20132019. J Glob Antimicrob Resist. 2022;29:527\u201333. https:\/\/doi.org\/10.1016\/j.jgar.2021.11.011.","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"13396_CR12","doi-asserted-by":"publisher","first-page":"dlad152","DOI":"10.1093\/jacamr\/dlad152","volume":"6","author":"JA Karlowsky","year":"2024","unstructured":"Karlowsky JA, Lob SH, Bauer KA, Esterly J, Siddiqui F, Young K, et al. Activity of ceftolozane\/tazobactam, imipenem\/relebactam and ceftazidime\/avibactam against clinical Gram-negative isolates-SMART United States 2019-21. JAC Antimicrob Resist. 2024;6(1):dlad152. https:\/\/doi.org\/10.1093\/jacamr\/dlad152.","journal-title":"JAC Antimicrob Resist"},{"key":"13396_CR13","unstructured":"Antimicrobial Resistance Surveillance Program (ARSP.) Annual Report. https:\/\/arsp.com.ph\/arsp-2022-annual-report-data-summary-is-now-available-for-download\/. Accessed 18 Feb 2026."},{"issue":"1","key":"13396_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","volume":"13","author":"F Barbier","year":"2023","unstructured":"Barbier F, Hraiech S, Kerneis S, Veluppillai N, Pajot O, Poissy J, et al. Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients. Ann Intensive Care. 2023;13(1):65. https:\/\/doi.org\/10.1186\/s13613-023-01153-6.","journal-title":"Ann Intensive Care"},{"key":"13396_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jgar.2022.04.011","volume":"30","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky JA, Bouchillon SK, Benaouda A, Soraa N, Zerouali K, Mohamed N, et al. Antimicrobial susceptibility testing of clinical isolates of Gram-negative bacilli collected in Morocco by the ATLAS Global Surveillance Program from 2018 to 2020. J Glob Antimicrob Resist. 2022;30:23\u201330. https:\/\/doi.org\/10.1016\/j.jgar.2022.04.011.","journal-title":"J Glob Antimicrob Resist"},{"key":"13396_CR16","unstructured":"Ceftazidime+Avibactam (ZAVICEFTA \u00ae). Prescribing information. Revised on 28 November 2024. https:\/\/wvpartner.pfizer.com\/webviewer\/labelcentral\/Labels\/ROWCOMP\/Philippines\/English\/LPD%20-%20Ceftazidime-avibactam%20-%20Zavicefta%20-%20PHL.pdf. Accessed 18 Feb 2026."},{"key":"13396_CR17","unstructured":"ATLAS Surveillance. Antimicrobial Testing Leadership and Surveillance. https:\/\/atlas-surveillance.com\/login. Accessed 18 Feb 2026."},{"key":"13396_CR18","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 33rd Edition. Document M100, Wayne, PA. 2023."},{"key":"13396_CR19","doi-asserted-by":"publisher","first-page":"100310","DOI":"10.1016\/j.lanwpc.2021.100310","volume":"18","author":"J Uy","year":"2022","unstructured":"Uy J, Van VTS, Ulep VG, Bayani DB, Walker D. The Impact of COVID-19 on Hospital Admissions for Twelve High-Burden Diseases and Five Common Procedures in the Philippines: A National Health Insurance Database Study 2019\u20132020. Lancet Reg Health West Pac. 2022;18:100310. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100310.","journal-title":"Lancet Reg Health West Pac"},{"key":"13396_CR20","doi-asserted-by":"publisher","first-page":"100585","DOI":"10.1016\/j.lanwpc.2022.100585","volume":"30","author":"J Maravilla","year":"2023","unstructured":"Maravilla J, Catiwa J, Guari\u00f1o R, Yap JF, Pagatpatan C, Orolfo DD, et al. Exploring indirect impacts of COVID-19 on local health systems from the perspectives of health workers and higher education stakeholders in the Philippines using a phenomenological approach. Lancet Reg Health West Pac. 2023;30:100585. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100585.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"13396_CR21","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1017\/ash.2025.48","volume":"5","author":"AZ Fazal","year":"2025","unstructured":"Fazal AZ, McGovern OL, Mahon GW, Lessa FC, Gler MT, Garcia J, et al. Trends in inpatient antibiotic use in Indonesia and the Philippines during the COVID-19 pandemic. Antimicrob Steward Healthc Epidemiol. 2025;5(1):e134. https:\/\/doi.org\/10.1017\/ash.2025.48.","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"issue":"2","key":"13396_CR22","doi-asserted-by":"publisher","first-page":"e00277","DOI":"10.1128\/spectrum.00277-22","volume":"10","author":"B Sacchetti","year":"2022","unstructured":"Sacchetti B, Travis J, Steed LL, Webb G. Effects of COVID-19 on Blood Culture Contamination at a Tertiary Care Academic Medical Center. Microbiol Spectr. 2022;10(2):e00277\u201322. https:\/\/doi.org\/10.1128\/spectrum.00277-22.","journal-title":"Microbiol Spectr"},{"issue":"4","key":"13396_CR23","doi-asserted-by":"publisher","first-page":"e01814","DOI":"10.1128\/aac.01814-18","volume":"63","author":"JA Karlowsky","year":"2019","unstructured":"Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2019;63(4):e01814\u201318. https:\/\/doi.org\/10.1128\/aac.01814-18.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"13396_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12866-022-02644-5","volume":"22","author":"P Jia","year":"2022","unstructured":"Jia P, Zhu Y, Zhang H, Cheng B, Guo P, Xu Y, et al. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. BMC Microbiol. 2022;22(1):234. https:\/\/doi.org\/10.1186\/s12866-022-02644-5.","journal-title":"BMC Microbiol"},{"issue":"2","key":"13396_CR25","first-page":"174","volume":"77","author":"TS Tuan Soh","year":"2022","unstructured":"Tuan Soh TS, Salvinder S, Chen VSY. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Malaysia: Results from the ATLAS Programme, 2013 to 2019. Med J Malaysia. 2022;77(2):174\u201384.","journal-title":"Med J Malaysia"},{"issue":"1","key":"13396_CR26","doi-asserted-by":"publisher","first-page":"115553","DOI":"10.1016\/j.diagmicrobio.2021.115553","volume":"102","author":"IG Bae","year":"2022","unstructured":"Bae IG, Stone GG. In vitro activity of ceftazidime-avibactam and comparators against bacterial isolates collected in South Korea as part of the ATLAS global surveillance program (2016\u20132018). Diagn Microbiol Infect Dis. 2022;102(1):115553. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115553.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"4","key":"13396_CR27","doi-asserted-by":"publisher","first-page":"e0185422","DOI":"10.1128\/spectrum.01854-22","volume":"10","author":"Y Guo","year":"2022","unstructured":"Guo Y, Han R, Jiang B, Ding L, Yang F, Zheng B, et al. In Vitro Activity of New beta-Lactam-beta-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022;10(4):e0185422. https:\/\/doi.org\/10.1128\/spectrum.01854-22.","journal-title":"Microbiol Spectr"},{"issue":"3","key":"13396_CR28","doi-asserted-by":"publisher","first-page":"dlac060","DOI":"10.1093\/jacamr\/dlac060","volume":"4","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky JA, Bouchillon SK, Kotb REM, Mohamed N, Stone GG, Sahm DF. Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme (2018-20). JAC Antimicrob Resist. 2022;4(3):dlac060. https:\/\/doi.org\/10.1093\/jacamr\/dlac060.","journal-title":"JAC Antimicrob Resist"},{"issue":"3","key":"13396_CR29","doi-asserted-by":"publisher","first-page":"114833","DOI":"10.1016\/j.diagmicrobio.2019.05.005","volume":"96","author":"HS Sader","year":"2020","unstructured":"Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017\u20132018). Diagn Microbiol Infect Dis. 2020;96(3):114833. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.05.005.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"13396_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/antibiotics11030355","volume":"11","author":"P Nulsopapon","year":"2022","unstructured":"Nulsopapon P, Pongchaidecha M, Nasomsong W, Polwichai P, Suphankong S, Sirichote P, et al. Antimicrobial Activity Profiles and Potential Antimicrobial Regimens against Carbapenem-Resistant Enterobacterales Isolated from Multi-Centers in Western Thailand. Antibiot (Basel). 2022;11(3):355. https:\/\/doi.org\/10.3390\/antibiotics11030355.","journal-title":"Antibiot (Basel)"},{"issue":"7","key":"13396_CR31","doi-asserted-by":"publisher","first-page":"e02569","DOI":"10.1128\/aac.02569-17","volume":"62","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother. 2018;62(7):e02569\u201317. https:\/\/doi.org\/10.1128\/aac.02569-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"13396_CR32","doi-asserted-by":"publisher","first-page":"8310","DOI":"10.1038\/s41598-024-59036-0","volume":"14","author":"G Kroneislova","year":"2024","unstructured":"Kroneislova G, Zavora J, Adamkova VG, Rydlova A, Adamkova V. In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study. Sci Rep. 2024;14(1):8310. https:\/\/doi.org\/10.1038\/s41598-024-59036-0.","journal-title":"Sci Rep"},{"issue":"4","key":"13396_CR33","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s12325-023-02436-x","volume":"40","author":"TA Le","year":"2023","unstructured":"Le TA, Hiba T, Chaudhari D, Preston AN, Palowsky ZR, Ahmadzadeh S, et al. Aminoglycoside-Related Nephrotoxicity and Ototoxicity in Clinical Practice: A Review of Pathophysiological Mechanism and Treatment Options. Adv Ther. 2023;40(4):1357\u201365. https:\/\/doi.org\/10.1007\/s12325-023-02436-x.","journal-title":"Adv Ther"},{"issue":"8","key":"13396_CR34","doi-asserted-by":"publisher","first-page":"e28283","DOI":"10.7759\/cureus.28283","volume":"14","author":"S Swaminathan","year":"2022","unstructured":"Swaminathan S, Routray A, Mane A. Early and Appropriate Use of Ceftazidime-Avibactam in the Management of Multidrug-Resistant Gram-Negative Bacterial Infections in the Indian Scenario. Cureus. 2022;14(8):e28283. https:\/\/doi.org\/10.7759\/cureus.28283.","journal-title":"Cureus"},{"issue":"1","key":"13396_CR35","doi-asserted-by":"publisher","first-page":"115652","DOI":"10.1016\/j.diagmicrobio.2022.115652","volume":"103","author":"YD Bakthavatchalam","year":"2022","unstructured":"Bakthavatchalam YD, Routray A, Mane A, Kamat S, Gupta A, Bari AK, et al. In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019. Diagn Microbiol Infect Dis. 2022;103(1):115652. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115652.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"13396_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12941-020-00355-1","volume":"19","author":"WC Ko","year":"2020","unstructured":"Ko WC, Stone GG. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017). Ann Clin Microbiol Antimicrob. 2020;19(1):14. https:\/\/doi.org\/10.1186\/s12941-020-00355-1.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"3","key":"13396_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ijmmb.2021.05.005","volume":"39","author":"P Sathe","year":"2021","unstructured":"Sathe P, Kamat S, Adhav C. Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients with nosocomial pneumonia: Subset analysis from the REPROVE study. Indian J Med Microbiol. 2021;39(3):363\u20136. https:\/\/doi.org\/10.1016\/j.ijmmb.2021.05.005.","journal-title":"Indian J Med Microbiol"},{"key":"13396_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijid.2020.01.022","volume":"93","author":"KL Li","year":"2020","unstructured":"Li KL, Abad CLR. The clinical profile and outcomes of adult patients given intravenous colistin for multidrug-resistant gram negative infections in a Philippine tertiary hospital. Int J Infect Dis. 2020;93:9\u201314. https:\/\/doi.org\/10.1016\/j.ijid.2020.01.022.","journal-title":"Int J Infect Dis"},{"issue":"4","key":"13396_CR39","doi-asserted-by":"publisher","first-page":"dlab159","DOI":"10.1093\/jacamr\/dlab159","volume":"3","author":"N Al-Sweih","year":"2021","unstructured":"Al-Sweih N, Jamal W, Mokaddas E, Habashy N, Kurdi A, Mohamed N. Evaluation of the in vitro activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012-19. JAC Antimicrob Resist. 2021;3(4):dlab159. https:\/\/doi.org\/10.1093\/jacamr\/dlab159.","journal-title":"JAC Antimicrob Resist"},{"issue":"6 Pt 2","key":"13396_CR40","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jmii.2021.07.007","volume":"55","author":"YC Chen","year":"2022","unstructured":"Chen YC, Chen WY, Hsu WY, Tang HJ, Chou Y, Chang YH, et al. Distribution of beta-lactamases and emergence of carbapenemases co-occurring Enterobacterales isolates with high-level antibiotic resistance identified from patients with intra-abdominal infection in the Asia-Pacific region, 2015\u20132018. J Microbiol Immunol Infect. 2022;55(6 Pt 2):1263\u201372. https:\/\/doi.org\/10.1016\/j.jmii.2021.07.007.","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"13396_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5365\/wpsar.2020.11.1.006","volume":"12","author":"J Chilam","year":"2021","unstructured":"Chilam J, Argimon S, Limas MT, Masim ML, Gayeta JM, Lagrada ML, et al. Genomic surveillance of Pseudomonas aeruginosa in the Philippines, 2013\u20132014. Western Pac Surveill Response J. 2021;12(2):4\u201318. https:\/\/doi.org\/10.5365\/wpsar.2020.11.1.006.","journal-title":"Western Pac Surveill Response J"},{"issue":"2","key":"13396_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","volume":"63","author":"D van Duin","year":"2016","unstructured":"van Duin D, Bonomo RA. Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation beta-Lactam\/beta-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016;63(2):234\u201341. https:\/\/doi.org\/10.1093\/cid\/ciw243.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"13396_CR43","doi-asserted-by":"publisher","first-page":"e0312923","DOI":"10.1128\/spectrum.03129-23","volume":"11","author":"T Riccobene","year":"2023","unstructured":"Riccobene T, Ai C, Yu KC, Gregory S, Kim B, Debabov D, et al. Real-world in vitro activity of newer antibiotics against Enterobacterales and Pseudomonas aeruginosa, including carbapenem-non-susceptible and multidrug-resistant isolates: a multicenter analysis. Microbiol Spectr. 2023;11(6):e0312923. https:\/\/doi.org\/10.1128\/spectrum.03129-23.","journal-title":"Microbiol Spectr"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13396-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13396-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:12:15Z","timestamp":1783347135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13396-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13396"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13396-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,10]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board (IRB) assessment was requested from the St Luke\u2019s Medical Center Institutional Ethics Review Committee (IERC), Davao Doctor\u2019s Hospital Research Ethics Committee (REC), and National Kidney and Transplant Institute Research Ethics Committee (REC). The collection of isolates and anonymized demographic patient data was done according to all relevant guidelines and regulations. Individual patient consent was assessed by IRB in each institution to be not needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MM declares no conflict of interest. EL has received honoraria from Pfizer for consultancy as speaker and advisory board member. MYB has received honoraria from Pfizer for consultancy as speaker and advisory board member. VW is a full-time employee of Pfizer Products India Private Limited and owns Pfizer stock. EP is a full-time employee of Pfizer Philippines Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1238"}}